• luminal
  • Invasive ductal carcinoma-no special type, as determined morphologically, is thought to arise exclusively from the luminal epithelial cells of the breast. (aacrjournals.org)
  • women
  • Breast cancer is the most common form of cancer and the second leading cause of malignancy-associated death in women worldwide. (diva-portal.org)
  • In this article, you will find information about the Olaparib (PARP inhibitors), first oral prescription medicine for women with BRCA-mutated advanced ovarian cancer which was approved in 2014. (cancerworld.info)
  • blood
  • An increased risk of getting an infection from a drop in white blood cells - it is harder to fight infections and the patient can become very ill. (cancerworld.info)
  • cells
  • PARP (poly (ADP-ribose) polymerase) inhibitors are a unique type of medication that works by inhibiting cancer cells from repairing their DNA once they have been destroyed by other chemotherapy agents. (cancerworld.info)
  • Because healthy cells don't have this defect, olaparib is able to target and kill cancer cells more specifically than normal chemotherapy drugs can. (cancerworld.info)
  • Targeted therapy is an outcome of about 100 years of investigation dedicated to understanding the differences between normal cells and cancer cells. (cancerworld.info)
  • Cancer treatment till now has concentrated primarily on the destruction of rapidly dividing cells because one feature of cancer cells is that they divide rapidly. (cancerworld.info)
  • Researchers look for particular differences in the cancer cells and the normal cells and then used this information to create a targeted therapy to attack the cancer cells without harming the normal cells. (cancerworld.info)
  • All kind of targeted therapy works a bit differently but all intervene the ability of the cancer cell to grow, divide, repair and interact with other cells. (cancerworld.info)
  • human
  • Vascular endothelial growth factor (VEGF) is considered a key mediator of tumor angiogenesis, including neovascularization in human breast cancer. (diva-portal.org)
  • therapy
  • PARP inhibitors give a hopeful option for targeted therapy in ovarian cancer and have an explicit advantage in BRCA mutation carriers. (cancerworld.info)
  • It is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstrsZeneca. (cancerworld.info)